Comment on FDA’s Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide
Reji Thomas, Mesut Cetin, Glen B. Baker, Serdar M. Dursun
( Psychiatry and Clinical Psychopharmacology 2016; 26: 329-331) DOI: 10.5455/bcp.20161027122045